Abstract 5138
Background
Reliable biomarkers to predict response to immunotherapy is crucial for patients’ counseling and decision making. This study was aimed to identify the role of CT radiomic features in predicting response to immunotherapy in patients with recurrent or metastatic urothelial carcinoma.
Methods
A total of 62 patients with their 224 lesions who underwent PD-1 and PD-L1 immunotherapy between March 2015 and November 2017 were retrospectively analyzed. The patients were temporally divided into training sets (n = 41; 155 lesions) and independent test set (n = 21; 69 lesions). For radiomics feature extraction, two radiologists independently segmented the region of interest at baseline CT on portal venous phase. A radiomics signature (RAD score) was built by using the least absolute shrinkage and selection operator (LASSO) method. The diagnostic performance of RAD score for prediction of response to immunotherapy was evaluated by C statistics.
Results
The overall response rate of immunotherapy was 36.6% in the training set and 28.8% in the test set. RAD score revealed the C statistics of 0.83 (95% CI, 0.68–0.93) in the training set and a corresponding C statistics of 0.71 (95% CI, 0.48–0.89) in the test set.
Conclusions
This study suggests that radiomic features extracted from metastatic masses at baseline CT are predictive of response to immunotherapy in patients with recurrent or metastatic urothelial carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2344 - Lung Cancer in Europe: strengthening policy responses to address unmet needs
Presenter: Mary Bussell
Session: Poster Display session 3
Resources:
Abstract
1359 - Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage
Presenter: Selina Wong
Session: Poster Display session 3
Resources:
Abstract
4433 - Acute Diagnostic Oncology Clinic: A Unique Primary Care-Oncology Service
Presenter: Abhijit Gill
Session: Poster Display session 3
Resources:
Abstract
3506 - THE NEW MUTATIONAL MODEL IN ONCOLOGY. What changes in welfare, clinical practice, research, and regulatory procedures
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3350 - Selection of a set of quality indicators (QI) for oncological clinical pathway
Presenter: Aude Fourcade
Session: Poster Display session 3
Resources:
Abstract
4400 - Sustainable drug prices at market launch: policy proposals and their empirical evidence
Presenter: Nora Fanzen
Session: Poster Display session 3
Resources:
Abstract
4118 - Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)
Presenter: Nathalie Olympios
Session: Poster Display session 3
Resources:
Abstract
1340 - The direct medical cost of breast cancer in a Belgian hospital
Presenter: Hannan Lemhouer
Session: Poster Display session 3
Resources:
Abstract
1863 - Does the healthcare system approaches cancer patients for using private services during diagnostic process?
Presenter: Karolina Osowiecka
Session: Poster Display session 3
Resources:
Abstract
2637 - Measuring financial toxicity of cancer in the Italian health care system: initial results of the patient reported outcome for Fighting Financial Toxicity of cancer project (proFFiT).
Presenter: Silvia Riva
Session: Poster Display session 3
Resources:
Abstract